<DOC>
	<DOCNO>NCT00130338</DOCNO>
	<brief_summary>The goal research study evaluate , open-label extension phase , effectiveness , tolerability safety rivastigmine capsule male female age 50 85 year old probable vascular dementia .</brief_summary>
	<brief_title>Rivastigmine Capsules Patients With Probable Vascular Dementia</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Patients complete doubleblind treatment phase drop early study , return remain schedule efficacy assessment ( retrieve dropout patient ) without significant protocol violation eligible participate . Retrieved dropout patient , treat cholinergic drug past 4 week</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Vascular</keyword>
	<keyword>Rivastigmine</keyword>
	<keyword>Stroke</keyword>
	<keyword>Memory loss</keyword>
</DOC>